search icon
      blog search icon

      Agile Therapeutics Inc. (AGRX) stock fell 1.29% today. Here’s what’s happening? - Stocks Telegraph

      By Mahnoor Shah

      Published on

      October 15, 2021

      1:58 PM UTC

      Agile Therapeutics Inc. (AGRX) stock fell 1.29% today. Here’s what’s happening? - Stocks Telegraph

      Agile Therapeutics Inc. (NASDAQ: AGRX) stock plunged by 0.37% at the last close while the AGRX stock price decline by 1.29% in the current market trading session. Agile Therapeutics is a women’s healthcare firm devoted to meeting today women’s unfulfilled health requirements.

      AGRX stock’ Recent Update

      Agile Therapeutics commended House Congressional Committee leaders for encouraging the Secretaries of Health and Human Services (HHS), Treasury, and Labor to enforce the law respecting women’s access to contraceptive methods as mandated by the Affordable Care Act (ACA).

      Al Altomari, Chairman, and CEO of Agile Therapeutics commented,

      They appreciate the letter’s authors, Energy and Commerce Committee Chairman Frank Pallone Jr., Ways and Means Committee Chairman Richard E Neal, Education and Labor Committee Chairman Robert C. Scott, and Oversight and Reform Committee Chairwoman Carolyn Maloney, for having brought this important matter to the attention. Contraception is a personal decision that all women should be able to choose in conjunction with their health care professionals.

      They also acknowledge the work of the Family Planning Coalition and its 35 members, who, on September 24, 2021, submitted a letter to the Secretaries expressing similar concerns about impediments to contraception access. They applaud these people and groups’ efforts to implement the ACA and guarantee that women have access to the birth control they require and are entitled to under the law.

      Past Development

      Agile Therapeutics confirmed recently that Josephine Torrente has been elected as a Class II director to the Company’s board of directors, starting October 7, 2021. Ms. Torrente will be a member of the Agile Science and Technology Committee, as well as the Nominating and Corporate Governance Committee.

      Al Altomari, Chairman, and CEO of AGRX stock stated,

      Josephine is an accomplished regulatory strategist with a wealth of expertise steering innovative medicinal treatments through the FDA clearance process. She’s also had a lot of expertise assisting firms and investors with pipeline and acquisition evaluations. They are sure that her unique regulatory expertise and strategic approach will enable her to contribute significantly to their Board as they pursue commercial development.

      More From Stocks telegraph